Platelet‐to‐Neutrophil Ratio: A Novel Prognostic Indicator for Anti‐PD‐1‐Based Therapy in Relapsed/Refractory Hodgkin Lymphoma and Solid Tumors

Documenti analoghi

• Venetoclax and Homoharringtonine‐Based Therapy Exhibited a Striking Response in Refractory/Relapsed Early T‐Cell Precursor Acute Lymphoblastic Leukemia
  di: Xiang Zhang, et al.
  Pubblicazione: (2025)
• The Role of Neutrophils and NETosis in Diseases: The Implications for Therapy
  di: Zhen Ma, et al.
  Pubblicazione: (2026)
• Genetic Subtype‐Based International Prognostic Index Prognostic Model in Diffuse Large B‐Cell Lymphoma
  di: Lan Mi, et al.
  Pubblicazione: (2025)
• Glycoprotein Ibα‐Dependent Platelet Activation is Essential for Tumor Cell–Platelet Interaction and Experimental Metastasis
  di: Kangxi Zhou, et al.
  Pubblicazione: (2025)
• Clinical Benefit of PD‐1/PD‐L1 Inhibitors as Standard First‐Line Treatment in Low PD‐L1‐Expressing Advanced Solid Tumors: A Systematic Review and Meta‐Analysis
  di: Peng Wu, et al.
  Pubblicazione: (2026)